News Scan for Jul 09, 2021 umn.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from umn.edu Daily Mail and Mail on Sunday newspapers.
Following is a transcript of their remarks:
Susan O Brien, MD: Hi, everyone, and welcome to this roundtable where we re going to discuss CLL presentations at ASH 2020 this year. I m Dr. Susan O Brien from the Chao Family Comprehensive Cancer Center at the University of California in Irvine, and I m joined by two esteemed colleagues, Dr. Jennifer Brown from Dana-Farber and Dr. Anthony Mato from Memorial Sloan Kettering.
We have two presentations today on the TRANSCEND clinical trial, and that is an interesting CAR-T trial of liso-cel which targets CD19, like many of the other CAR-Ts, but is a little bit different in that it has a defined component of CD4 and CD8 cells, which I think is the only CAR-T that s actually doing that. One of the presentations involved just the CAR-T alone and the other was the CAR-T given in combination with ibrutinib. Jennifer, maybe you could speak to that and the rationale for actually giving it with ibrutinib in the sense that many of the patients had
Following is a transcript of their remarks:
Susan O Brien, MD: Hi, everyone, and welcome to this roundtable where we re going to discuss CLL presentations at ASH 2020 this year. I m Dr. Susan O Brien from the Chao Family Comprehensive Cancer Center at the University of California in Irvine, and I m joined by two esteemed colleagues, Dr. Jennifer Brown from Dana-Farber and Dr. Anthony Mato from Memorial Sloan Kettering.
An interesting presentation at ASH this year that many people were looking forward to was the trial looking at the combination of what s called U2, which is a novel anti-CD20 antibody, ublituximab, combined with a novel PI3K delta inhibitor, umbralisib. In this randomized trial, the comparator arm was obinutuzumab with chlorambucil and it was interesting because the trial actually included both previously untreated as well as previously treated patients. Jennifer, do you want to talk about some of the results from this trial?
email article So our marketing team said Why don t we pitch Marvel that our nurses are the true superheroes? Claire Zangerle, RN, chief nurse executive at Allegheny Health Network in Pittsburgh, on the origin story of the comic book that gave front-line nurses a Marvel makeover. I m scared to death. Gail Engel, age 65, founder and administrator of the Grand Family Coalition in Colorado, on the threat of COVID-19 infection she faces as an older caretaker raising her grandson. These are patients that we may not be thinking about that may be at risk of substance abuse. Carlos Arteaga, MD, of the University of Texas Southwestern School of Medicine in Dallas, discussing research about persistent opioid use in women following breast cancer surgery.
At December s has brought together three expert leaders in their field:
Moderator Susan O Brien, MD, of Chao Family Comprehensive Cancer Center, University of California Irvine Health, is joined by Jennifer R. Brown, MD, Director of the CLL Center at Dana-Farber Cancer Institute, and Anthony Mato, MD, Director of the CLL Program at Memorial Sloan Kettering Cancer Center, for a virtual roundtable discussion on the new and potentially practice-changing data from the meeting.
In this first of four exclusive MedPage Today
episodes, the discussion centers on the studies focused on combined ibrutinib plus venetoclax therapy, including the phase II CAPTIVATE study.